# Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

> **NCT07187908** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 1076 (estimated)

## Conditions studied

- Primary/Secondary Prevention
- High Risk for Febrile Neutropenia of Chemotherapy Regimens
- Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia

## Interventions

- **DRUG:** Efbemalenograstim alfa Injection

## Key facts

- **NCT ID:** NCT07187908
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 1076 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187908, "Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07187908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*